IR
Superintel
OverviewMarketsWatchlist
© 2026 IR SuperintelMethodologyContact

Imprimis Pharmaceuticals Inc

CUSIP: 45323A201 | 79 institutional holders

Quarters

Q1 2020Q4 2019Q3 2019Q2 2019Q1 2019
CompareDetailedHistoricalFundsOptions13D/13GPeersTargetingTrading SummaryProfile

Institutional Holders — Q1 2020

Opaleye Management Inc.2,500,000
0.0% of portfolio›$9.6K
Proequities, Inc.0
0.0% of portfolio›$0
StyleTurnoverLocationFiled
Opaleye Management Inc.
2,500,000$9.6K0.0%Agg GrowthMediumBoston, MA2020-05-15
Proequities, Inc.
0$00.0%GrowthVery LowBirmingham, AL2020-05-13